Cargando…

Plasma Levels of High-Mobility Group Box 1 during Peptide Vaccination in Patients with Recurrent Ovarian Cancer

High-mobility group box 1 (HMGB1) is a nuclear protein that is known to be secreted into extracellular fluids from injured cells, activated macrophages, and tumor cells. The clinical correlation of circulating HMGB1 levels with various diseases including cancer has been reported. However, there is n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Waki, Kayoko, Kawano, Kouichiro, Tsuda, Naotake, Ushijima, Kimio, Itoh, Kyogo, Yamada, Akira
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5426075/ https://www.ncbi.nlm.nih.gov/pubmed/28536706 http://dx.doi.org/10.1155/2017/1423683

Ejemplares similares

Personalized peptide vaccination for cervical cancer patients who have received prior platinum-based chemotherapy
por: Kawano, Kouichiro, et al.
Publicado: (2015)

CD4/CD8 ratio is a prognostic factor in IgG nonresponders among peptide vaccine‐treated ovarian cancer patients
por: Waki, Kayoko, et al.
Publicado: (2020)

Integrity of plasma DNA is inversely correlated with vaccine-induced antitumor immunity in ovarian cancer patients
por: Waki, Kayoko, et al.
Publicado: (2020)

Integrity of plasma cell-free DNA as a prognostic factor for vaccine therapy in patients with endometrial cancer
por: Waki, Kayoko, et al.
Publicado: (2021)

Identification of B cell epitopes reactive to human papillomavirus type-16L1- derived peptides
por: Fukui, Akimasa, et al.
Publicado: (2012)

Epithelial borderline ovarian tumor: Diagnosis and treatment strategy
por: Ushijima, Kimio, et al.
Publicado: (2015)

Blockade of high mobility group box 1 augments antitumor T‐cell response induced by peptide vaccination as a co‐adjuvant
por: Waki, Kayoko, et al.
Publicado: (2016)

Concurrent chemoradiotherapy with low-dose daily cisplatin for high risk uterine cervical cancer: a long-term follow-up study
por: Ushijima, Kimio, et al.
Publicado: (2013)

Prevention of lymphocele development in gynecologic cancers by the electrothermal bipolar vessel sealing device
por: Tsuda, Naotake, et al.
Publicado: (2014)

Identification of appropriate cone length to avoid positive cone margin in high grade cervical intraepithelial neoplasia
por: Kawano, Kouichiro, et al.
Publicado: (2016)

Chemotherapy and molecular targeting therapy for recurrent cervical cancer
por: Tsuda, Naotake, et al.
Publicado: (2016)

Immunological efficacy of herbal medicines in prostate cancer patients treated by personalized peptide vaccine
por: Koga, Noriko, et al.
Publicado: (2017)

Suppression of high mobility group box 1 in B16F10 tumor does not inhibit the induction of neoantigen‐specific T cells
por: Waki, Kayoko, et al.
Publicado: (2022)

Treatment for Recurrent Ovarian Cancer—At First Relapse
por: Ushijima, Kimio
Publicado: (2010)

Knockout of high-mobility group box 1 in B16F10 melanoma cells induced host immunity-mediated suppression of in vivo tumor growth
por: Yokomizo, Kanako, et al.
Publicado: (2022)

Immunological evaluation of peptide vaccination for cancer patients with the HLA-A26 allele
por: Sakamoto, Shinjiro, et al.
Publicado: (2015)

A case of minimal uterine serous carcinoma with distant lymph node metastasis without peritoneal dissemination
por: Kawano, Kouichiro, et al.
Publicado: (2011)

Trends and characteristics of fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer in Japan: a survey by the Gynecologic Oncology Committee of the Japan Society of Obstetrics and Gynecology
por: Ushijima, Kimio, et al.
Publicado: (2023)

Expression of the SART‐1 Antigens in Uterine Cancers
por: Matsumoto, Hajime, et al.
Publicado: (1998)

Immunological evaluation of peptide vaccination for cancer patients with the HLA ‐A11(+) or ‐A33(+) allele
por: Sakamoto, Shinjiro, et al.
Publicado: (2017)

Expression of Tumor‐rejection Antigens in Gynecologic Cancers
por: Tanaka, Shoko, et al.
Publicado: (2000)

Plasma level of prostate related-antigen peptide-reactive IgG is a prognostic factor of patients with breast cancer treated with personalized peptide vaccines
por: Saku, Shuko, et al.
Publicado: (2021)

PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer
por: Waki, Kayoko, et al.
Publicado: (2014)

Identification of biomarkers for personalized peptide vaccination in 2,588 cancer patients
por: Suekane, Shigetaka, et al.
Publicado: (2020)

Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer
por: Nishio, Shin, et al.
Publicado: (2017)

Survival analysis of multiple peptide vaccination for the selection of correlated peptides in urological cancers
por: Noguchi, Masanori, et al.
Publicado: (2018)

Identification of novel Lck‐derived T helper epitope long peptides applicable for HLA‐A2(+) cancer patients as cancer vaccine
por: Matsueda, Satoko, et al.
Publicado: (2015)

Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients
por: Takahashi, Ryuji, et al.
Publicado: (2014)

Dynamics in the expression of programmed death ligand 1 and cluster of differentiation 163 in the tumor microenvironment of uterine cervical cancer: a single-center retrospective study
por: Miyata, Yusaku, et al.
Publicado: (2023)

Pivotal role of High-Mobility Group Box 2 in ovarian folliculogenesis and fertility
por: Shirouzu, Shinichiro, et al.
Publicado: (2022)

Investigation of factors associated with reduced clinical benefits of personalized peptide vaccination for pancreatic cancer
por: Uchino, Yoshihiro, et al.
Publicado: (2021)

Juzentaihoto Failed to Augment Antigen-Specific Immunity but Prevented Deterioration of Patients' Conditions in Advanced Pancreatic Cancer under Personalized Peptide Vaccine
por: Yutani, Shigeru, et al.
Publicado: (2013)

A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time
por: Noguchi, Masanori, et al.
Publicado: (2013)

Personalized peptide vaccination for advanced colorectal cancer
por: Sasada, Tetsuro, et al.
Publicado: (2015)

Correction: Pivotal role of High-Mobility Group Box 2 in ovarian folliculogenesis and fertility
por: Shirouzu, Shinichiro, et al.
Publicado: (2023)

Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies
por: Yutani, Shigeru, et al.
Publicado: (2017)

High mobility group box 1: as a 'testament' mediator
por: Maruyama, I, et al.
Publicado: (2005)

Antitumor activity of antibody against cytotoxic T lymphocyte epitope peptide of lymphocyte‐specific protein tyrosine kinase
por: Matsueda, Satoko, et al.
Publicado: (2018)

Urinary and serum levels of high mobility group box 1
por: Nakamura, Toshihiko, et al.
Publicado: (2023)

Association of plasma level of high-mobility group box-1 with necroptosis and sepsis outcomes
por: Yoo, Hongseok, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kg3ifa1h0avn1tb5i35529rq0e